Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
Status:
Recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
This is an open label, multicenter, Phase 2 study designed to assess the efficacy and safety
of tislelizumab in combination with fruquintinib in participants with advanced or metastatic,
unresectable gastric cancer (GC), or colorectal cancer (CRC) or Non-small Cell Lung Cancer
(NSCLC). The study will be conducted in 2 parts. Part 1 will be the safety run-in stage to
determine dose-limiting toxicity (DLT) and recommended Phase 2 dose (RP2D). Part 2 will
assess the preliminary efficacy of tislelizumab in combination with fruquintinib in
participants as measured by the overall response rate (ORR) and other efficacy and safety
profiles.